Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib Mesylate in Hypereosinophilic Syndromes and Chronic Eosinophilic Leukemia (NILG)
2004-002280-24Phase 2Completed
- Sponsor
- Papa Giovanni XXIII Hospital
- Start
- Sep 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in hypereosinophilic syndrome (HES) and chronic eosinophilic leukemia (CEL), sponsored by Papa Giovanni XXIII Hospital. Started Sep 2004; status: completed.
02
Drugs
03
Conditions
hypereosinophilic syndrome (HES)chronic eosinophilic leukemia (CEL)
Beyond the preview
Go deeper on 2004-002280-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002280-24.